GU Cancer

Ovarian cancer biomarker identifies more women susceptible to PARP inhibitor therapy

Australian researchers have discovered an epigenetic biomarker that may help identify more women with ovarian cancer who will be susceptible to PARP inhibitor therapy.A team at the Walter and Eliza Hall Institute (WEHI) in Melbourne have found that epigenetic marks for RAD51C gene silencing are required to avoid ovarian cancer cells developing resistance to PARP ...

Already a member?

Login to keep reading.

© 2022 the limbic